questionsmedicales.fr
Composés hétérocycliques
Composés hétéromonocycliques
Pyridines
Composés de pyridinium
Composés de pyridinium : Questions médicales fréquentes
Termes MeSH sélectionnés :
Diagnostic
5
Intoxication
Tests sanguins
Analyse chromatographique
Spectrométrie
Nausées
Troubles neurologiques
Tests urinaires
Métabolites
Historique médical
Symptômes
Symptômes
5
Douleurs abdominales
Troubles respiratoires
Éruptions cutanées
Irritations
Évolution des symptômes
Intervention rapide
Prévention
5
Équipements de protection
Exposition
Formations
Sécurité chimique
Fuites
Protocoles de sécurité
Traitements
5
Décontamination
Antidotes
Soins de soutien
Hydratation
Surveillance
Complications
Complications
5
Lésions organiques
Troubles respiratoires
Effets à long terme
Troubles cognitifs
Prise en charge médicale
Suivi régulier
Intervention rapide
Traitement approprié
Difficultés respiratoires
Confusion mentale
Facteurs de risque
5
Travailleurs en chimie
Industrie
Jeunes enfants
Personnes âgées
Antécédents médicaux
Maladies respiratoires
Conditions environnementales
Chaleur
Interactions médicamenteuses
Toxicité
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Composés de pyridinium : Questions médicales les plus fréquentes",
"headline": "Composés de pyridinium : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Composés de pyridinium : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-04-05",
"dateModified": "2025-03-31",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Composés de pyridinium"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Pyridines",
"url": "https://questionsmedicales.fr/mesh/D011725",
"about": {
"@type": "MedicalCondition",
"name": "Pyridines",
"code": {
"@type": "MedicalCode",
"code": "D011725",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.383.725"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Cétylpyridinium",
"alternateName": "Cetylpyridinium",
"url": "https://questionsmedicales.fr/mesh/D002594",
"about": {
"@type": "MedicalCondition",
"name": "Cétylpyridinium",
"code": {
"@type": "MedicalCode",
"code": "D002594",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.383.725.762.232"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Diquat",
"alternateName": "Diquat",
"url": "https://questionsmedicales.fr/mesh/D004178",
"about": {
"@type": "MedicalCondition",
"name": "Diquat",
"code": {
"@type": "MedicalCode",
"code": "D004178",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.383.725.762.352"
}
}
},
{
"@type": "MedicalWebPage",
"name": "1-Méthyl-4-phényl-pyridinium",
"alternateName": "1-Methyl-4-phenylpyridinium",
"url": "https://questionsmedicales.fr/mesh/D015655",
"about": {
"@type": "MedicalCondition",
"name": "1-Méthyl-4-phényl-pyridinium",
"code": {
"@type": "MedicalCode",
"code": "D015655",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.383.725.762.550"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Chlorure d'obidoxime",
"alternateName": "Obidoxime Chloride",
"url": "https://questionsmedicales.fr/mesh/D009768",
"about": {
"@type": "MedicalCondition",
"name": "Chlorure d'obidoxime",
"code": {
"@type": "MedicalCode",
"code": "D009768",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.383.725.762.600"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Paraquat",
"alternateName": "Paraquat",
"url": "https://questionsmedicales.fr/mesh/D010269",
"about": {
"@type": "MedicalCondition",
"name": "Paraquat",
"code": {
"@type": "MedicalCode",
"code": "D010269",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.383.725.762.621"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Bromure de pyridostigmine",
"alternateName": "Pyridostigmine Bromide",
"url": "https://questionsmedicales.fr/mesh/D011729",
"about": {
"@type": "MedicalCondition",
"name": "Bromure de pyridostigmine",
"code": {
"@type": "MedicalCode",
"code": "D011729",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.383.725.762.740"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Trimédoxime",
"alternateName": "Trimedoxime",
"url": "https://questionsmedicales.fr/mesh/D014289",
"about": {
"@type": "MedicalCondition",
"name": "Trimédoxime",
"code": {
"@type": "MedicalCode",
"code": "D014289",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.383.725.762.900"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Viologènes",
"alternateName": "Viologens",
"url": "https://questionsmedicales.fr/mesh/D014755",
"about": {
"@type": "MedicalCondition",
"name": "Viologènes",
"code": {
"@type": "MedicalCode",
"code": "D014755",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.383.725.762.925"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Benzyl viologène",
"alternateName": "Benzyl Viologen",
"url": "https://questionsmedicales.fr/mesh/D001594",
"about": {
"@type": "MedicalCondition",
"name": "Benzyl viologène",
"code": {
"@type": "MedicalCode",
"code": "D001594",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.383.725.762.925.100"
}
}
}
]
}
],
"about": {
"@type": "MedicalCondition",
"name": "Composés de pyridinium",
"alternateName": "Pyridinium Compounds",
"code": {
"@type": "MedicalCode",
"code": "D011726",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Sungwoo Hong",
"url": "https://questionsmedicales.fr/author/Sungwoo%20Hong",
"affiliation": {
"@type": "Organization",
"name": "Department of Chemistry, Korea Advanced Institute of Science and Technology (KAIST) Daejeon 34141 Korea hongorg@kaist.ac.kr."
}
},
{
"@type": "Person",
"name": "Werner Fudickar",
"url": "https://questionsmedicales.fr/author/Werner%20Fudickar",
"affiliation": {
"@type": "Organization",
"name": "Department of Chemistry, University of Potsdam, Potsdam, Germany."
}
},
{
"@type": "Person",
"name": "Torsten Linker",
"url": "https://questionsmedicales.fr/author/Torsten%20Linker",
"affiliation": {
"@type": "Organization",
"name": "Department of Chemistry, University of Potsdam, Potsdam, Germany."
}
},
{
"@type": "Person",
"name": "Lihua Luo",
"url": "https://questionsmedicales.fr/author/Lihua%20Luo",
"affiliation": {
"@type": "Organization",
"name": "Key Laboratory of Green Chemistry and Technology, Ministry of Education, College of Chemistry, Sichuan University, Chengdu, Sichuan 610064, P. R. China."
}
},
{
"@type": "Person",
"name": "Rui Sun",
"url": "https://questionsmedicales.fr/author/Rui%20Sun",
"affiliation": {
"@type": "Organization",
"name": "Key Laboratory of Green Chemistry and Technology, Ministry of Education, College of Chemistry, Sichuan University, Chengdu, Sichuan 610064, P. R. China."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "[Potential teratogenicity of modafinil - Conflicting evidence, need for research].",
"datePublished": "2023-01-13",
"url": "https://questionsmedicales.fr/article/36642328",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.gofs.2023.01.003"
}
},
{
"@type": "ScholarlyArticle",
"name": "A sustainable photochemical aerobic sulfide oxidation: access to sulforaphane and modafinil.",
"datePublished": "2022-07-27",
"url": "https://questionsmedicales.fr/article/35838682",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1039/d2ob01066f"
}
},
{
"@type": "ScholarlyArticle",
"name": "Infant Exposure to Armodafinil Through Human Milk Following Maternal Use of Modafinil.",
"datePublished": "2022-11-16",
"url": "https://questionsmedicales.fr/article/36384330",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1177/08903344221134273"
}
},
{
"@type": "ScholarlyArticle",
"name": "The Structural Basis of the Activity Cliff in Modafinil-Based Dopamine Transporter Inhibitors.",
"datePublished": "2024-06-17",
"url": "https://questionsmedicales.fr/article/38927116",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/biom14060713"
}
},
{
"@type": "ScholarlyArticle",
"name": "Psychostimulants Modafinil, Atomoxetine and Guanfacine Impair Bone Cell Differentiation and MSC Migration.",
"datePublished": "2022-09-06",
"url": "https://questionsmedicales.fr/article/36142172",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/ijms231810257"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Composés hétérocycliques",
"item": "https://questionsmedicales.fr/mesh/D006571"
},
{
"@type": "ListItem",
"position": 3,
"name": "Composés hétéromonocycliques",
"item": "https://questionsmedicales.fr/mesh/D006573"
},
{
"@type": "ListItem",
"position": 4,
"name": "Pyridines",
"item": "https://questionsmedicales.fr/mesh/D011725"
},
{
"@type": "ListItem",
"position": 5,
"name": "Composés de pyridinium",
"item": "https://questionsmedicales.fr/mesh/D011726"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Composés de pyridinium - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Composés de pyridinium",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-11",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Composés de pyridinium",
"description": "Comment diagnostiquer une intoxication aux composés de pyridinium ?\nQuels tests sont utilisés pour détecter les composés de pyridinium ?\nQuels symptômes indiquent une exposition aux pyridiniums ?\nLes tests urinaires peuvent-ils détecter les pyridiniums ?\nQuelle est l'importance de l'historique médical dans le diagnostic ?",
"url": "https://questionsmedicales.fr/mesh/D011726?mesh_terms=Modafinil#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Composés de pyridinium",
"description": "Quels sont les symptômes courants d'une exposition aux pyridiniums ?\nLes composés de pyridinium provoquent-ils des effets neurologiques ?\nY a-t-il des symptômes cutanés associés aux pyridiniums ?\nLes symptômes varient-ils selon le type de pyridinium ?\nComment les symptômes évoluent-ils avec le temps ?",
"url": "https://questionsmedicales.fr/mesh/D011726?mesh_terms=Modafinil#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Composés de pyridinium",
"description": "Quelles mesures préventives peuvent réduire l'exposition aux pyridiniums ?\nLes formations sont-elles nécessaires pour manipuler des pyridiniums ?\nComment stocker les composés de pyridinium en toute sécurité ?\nLes fuites de pyridiniums peuvent-elles être évitées ?\nQuelles sont les recommandations pour les laboratoires ?",
"url": "https://questionsmedicales.fr/mesh/D011726?mesh_terms=Modafinil#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Composés de pyridinium",
"description": "Quel est le traitement principal en cas d'intoxication aux pyridiniums ?\nLes soins de soutien sont-ils nécessaires pour les patients exposés ?\nQuels antidotes sont utilisés contre les pyridiniums ?\nLa dialyse est-elle efficace pour éliminer les pyridiniums ?\nComment prévenir les complications lors du traitement ?",
"url": "https://questionsmedicales.fr/mesh/D011726?mesh_terms=Modafinil#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Composés de pyridinium",
"description": "Quelles complications peuvent survenir après une exposition aux pyridiniums ?\nLes effets à long terme des pyridiniums sont-ils connus ?\nComment les complications sont-elles gérées ?\nLes complications peuvent-elles être évitées ?\nQuels sont les signes d'alerte pour des complications graves ?",
"url": "https://questionsmedicales.fr/mesh/D011726?mesh_terms=Modafinil#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Composés de pyridinium",
"description": "Quels sont les principaux facteurs de risque d'exposition aux pyridiniums ?\nL'âge influence-t-il la sensibilité aux pyridiniums ?\nLes antécédents médicaux augmentent-ils le risque d'intoxication ?\nLes conditions environnementales jouent-elles un rôle ?\nLes interactions médicamenteuses sont-elles un facteur de risque ?",
"url": "https://questionsmedicales.fr/mesh/D011726?mesh_terms=Modafinil#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une intoxication aux composés de pyridinium ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur l'historique d'exposition et des tests sanguins spécifiques."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour détecter les composés de pyridinium ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des analyses chromatographiques et spectrométriques sont couramment utilisées."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent une exposition aux pyridiniums ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent des nausées, des vomissements et des troubles neurologiques."
}
},
{
"@type": "Question",
"name": "Les tests urinaires peuvent-ils détecter les pyridiniums ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certains tests urinaires peuvent révéler la présence de métabolites pyridiniques."
}
},
{
"@type": "Question",
"name": "Quelle est l'importance de l'historique médical dans le diagnostic ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'historique médical aide à établir un lien entre les symptômes et l'exposition aux pyridiniums."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes courants d'une exposition aux pyridiniums ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent des douleurs abdominales, des vertiges et des troubles respiratoires."
}
},
{
"@type": "Question",
"name": "Les composés de pyridinium provoquent-ils des effets neurologiques ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent causer des maux de tête, des convulsions et des troubles de la conscience."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes cutanés associés aux pyridiniums ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des éruptions cutanées et des irritations peuvent survenir après contact avec ces composés."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon le type de pyridinium ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes peuvent varier en fonction de la structure chimique et de la dose."
}
},
{
"@type": "Question",
"name": "Comment les symptômes évoluent-ils avec le temps ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes peuvent s'aggraver sans traitement approprié, nécessitant une intervention rapide."
}
},
{
"@type": "Question",
"name": "Quelles mesures préventives peuvent réduire l'exposition aux pyridiniums ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Utiliser des équipements de protection individuelle lors de la manipulation de ces composés."
}
},
{
"@type": "Question",
"name": "Les formations sont-elles nécessaires pour manipuler des pyridiniums ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des formations sur la sécurité chimique sont essentielles pour les travailleurs exposés."
}
},
{
"@type": "Question",
"name": "Comment stocker les composés de pyridinium en toute sécurité ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les stocker dans des contenants hermétiques et étiquetés, à l'écart des sources de chaleur."
}
},
{
"@type": "Question",
"name": "Les fuites de pyridiniums peuvent-elles être évitées ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, en vérifiant régulièrement les équipements et en respectant les protocoles de sécurité."
}
},
{
"@type": "Question",
"name": "Quelles sont les recommandations pour les laboratoires ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les laboratoires doivent suivre des protocoles stricts de manipulation et de stockage des pyridiniums."
}
},
{
"@type": "Question",
"name": "Quel est le traitement principal en cas d'intoxication aux pyridiniums ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement principal est la décontamination et l'administration d'antidotes spécifiques."
}
},
{
"@type": "Question",
"name": "Les soins de soutien sont-ils nécessaires pour les patients exposés ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des soins de soutien, comme l'hydratation et la surveillance, sont souvent requis."
}
},
{
"@type": "Question",
"name": "Quels antidotes sont utilisés contre les pyridiniums ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des antidotes comme l'atropine peuvent être administrés pour contrer les effets toxiques."
}
},
{
"@type": "Question",
"name": "La dialyse est-elle efficace pour éliminer les pyridiniums ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "La dialyse peut être envisagée dans les cas graves d'intoxication pour éliminer les toxines."
}
},
{
"@type": "Question",
"name": "Comment prévenir les complications lors du traitement ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une surveillance étroite et un traitement rapide des symptômes sont essentiels pour prévenir les complications."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir après une exposition aux pyridiniums ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications comme des lésions organiques, des troubles neurologiques et respiratoires peuvent survenir."
}
},
{
"@type": "Question",
"name": "Les effets à long terme des pyridiniums sont-ils connus ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des effets à long terme incluent des troubles cognitifs et des problèmes respiratoires chroniques."
}
},
{
"@type": "Question",
"name": "Comment les complications sont-elles gérées ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications nécessitent une prise en charge médicale spécialisée et un suivi régulier."
}
},
{
"@type": "Question",
"name": "Les complications peuvent-elles être évitées ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une intervention rapide et un traitement approprié peuvent réduire le risque de complications."
}
},
{
"@type": "Question",
"name": "Quels sont les signes d'alerte pour des complications graves ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes comme des difficultés respiratoires, des convulsions ou une confusion mentale doivent alerter."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque d'exposition aux pyridiniums ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les travailleurs en chimie, agriculture et industrie sont les plus exposés aux pyridiniums."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il la sensibilité aux pyridiniums ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les jeunes enfants et les personnes âgées sont plus sensibles aux effets toxiques."
}
},
{
"@type": "Question",
"name": "Les antécédents médicaux augmentent-ils le risque d'intoxication ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents de maladies respiratoires ou neurologiques peuvent augmenter le risque."
}
},
{
"@type": "Question",
"name": "Les conditions environnementales jouent-elles un rôle ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des conditions comme la chaleur ou l'humidité peuvent exacerber les effets des pyridiniums."
}
},
{
"@type": "Question",
"name": "Les interactions médicamenteuses sont-elles un facteur de risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines interactions médicamenteuses peuvent augmenter la toxicité des pyridiniums."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 31/03/2025
Contenu vérifié selon les dernières recommandations médicales
4 publications dans cette catégorie
Affiliations :
Department of Chemistry, Korea Advanced Institute of Science and Technology (KAIST) Daejeon 34141 Korea hongorg@kaist.ac.kr.
Center for Catalytic Hydrocarbon Functionalizations, Institute for Basic Science (IBS) Daejeon 34141 Korea.
Publications dans "Composés de pyridinium" :
2 publications dans cette catégorie
Affiliations :
Department of Chemistry, University of Potsdam, Potsdam, Germany.
Publications dans "Composés de pyridinium" :
2 publications dans cette catégorie
Affiliations :
Department of Chemistry, University of Potsdam, Potsdam, Germany.
Publications dans "Composés de pyridinium" :
2 publications dans cette catégorie
Affiliations :
Key Laboratory of Green Chemistry and Technology, Ministry of Education, College of Chemistry, Sichuan University, Chengdu, Sichuan 610064, P. R. China.
Publications dans "Composés de pyridinium" :
2 publications dans cette catégorie
Affiliations :
Key Laboratory of Green Chemistry and Technology, Ministry of Education, College of Chemistry, Sichuan University, Chengdu, Sichuan 610064, P. R. China.
Publications dans "Composés de pyridinium" :
2 publications dans cette catégorie
Affiliations :
Xi'an Medical University, Xi'an, Shaanxi 710021, P. R. China.
Publications dans "Composés de pyridinium" :
2 publications dans cette catégorie
Affiliations :
Key Laboratory of Green Chemistry and Technology, Ministry of Education, College of Chemistry, Sichuan University, Chengdu, Sichuan 610064, P. R. China.
Publications dans "Composés de pyridinium" :
2 publications dans cette catégorie
Affiliations :
Key Laboratory of Green Chemistry and Technology, Ministry of Education, College of Chemistry, Sichuan University, Chengdu, Sichuan 610064, P. R. China.
Publications dans "Composés de pyridinium" :
2 publications dans cette catégorie
Affiliations :
Key Laboratory of Green Chemistry and Technology, Ministry of Education, College of Chemistry, Sichuan University, Chengdu, Sichuan 610064, P. R. China.
Publications dans "Composés de pyridinium" :
2 publications dans cette catégorie
Affiliations :
Key Laboratory of Green Chemistry and Technology, Ministry of Education, College of Chemistry, Sichuan University, Chengdu, Sichuan 610064, P. R. China.
Publications dans "Composés de pyridinium" :
2 publications dans cette catégorie
Affiliations :
Department of Chemistry, Korea Advanced Institute of Science and Technology (KAIST) Daejeon 34141 Korea hongorg@kaist.ac.kr.
Center for Catalytic Hydrocarbon Functionalizations, Institute for Basic Science (IBS) Daejeon 34141 Korea.
Publications dans "Composés de pyridinium" :
2 publications dans cette catégorie
Affiliations :
Georg-August Universität Göttingen , Tammannstraße 2 , 37077 Göttingen , Germany.
Publications dans "Composés de pyridinium" :
2 publications dans cette catégorie
Affiliations :
Georg-August Universität Göttingen , Tammannstraße 2 , 37077 Göttingen , Germany.
Publications dans "Composés de pyridinium" :
2 publications dans cette catégorie
Affiliations :
Key Laboratory of Applied Surface and Colloid Chemistry, Ministry of Education and School of Chemistry and Chemical Engineering, Shaanxi Normal University, Xi'an 710119, China.
Publications dans "Composés de pyridinium" :
2 publications dans cette catégorie
Affiliations :
Department of Pediatrics, Carver College of Medicine, University of Iowa, Iowa City, Iowa, USA.
Publications dans "Composés de pyridinium" :
2 publications dans cette catégorie
Affiliations :
Department of Chemistry and Biochemistry, Northern Illinois University, DeKalb, Illinois, USA.
Publications dans "Composés de pyridinium" :
2 publications dans cette catégorie
Affiliations :
Department of Medicine, Section of Infectious Disease, University of Wisconsin, Madison, Wisconsin, USA.
Department of Medical Microbiology and Immunology, University of Wisconsin, Madison Wisconsin, USA.
Publications dans "Composés de pyridinium" :
2 publications dans cette catégorie
Affiliations :
Department of Medicine, Section of Infectious Disease, University of Wisconsin, Madison, Wisconsin, USA.
Department of Medical Microbiology and Immunology, University of Wisconsin, Madison Wisconsin, USA.
Publications dans "Composés de pyridinium" :
2 publications dans cette catégorie
Affiliations :
Department of Medicine, Section of Infectious Disease, University of Wisconsin, Madison, Wisconsin, USA.
Department of Medical Microbiology and Immunology, University of Wisconsin, Madison Wisconsin, USA.
Publications dans "Composés de pyridinium" :
2 publications dans cette catégorie
Affiliations :
Department of Medicine, Section of Infectious Disease, University of Wisconsin, Madison, Wisconsin, USA.
Department of Medical Microbiology and Immunology, University of Wisconsin, Madison Wisconsin, USA.
Publications dans "Composés de pyridinium" :
Central disorders of hypersomnolence include narcolepsy type 1, narcolepsy type 2, idiopathic hypersomnia and hypersomnia associated with medical or mental disorders. Treatment is both non-pharmacolog...
Sulfoxide-containing molecules are an important class of compounds in the pharmaceutical industry and many efforts have been made to develop new and green protocols, targeting the chemoselective trans...
Narcolepsy, a condition adversely affecting psychological, social, and cognitive function, is more prevalent in females of childbearing age than the general population. Modafinil and armodafinil are c...
In this case study, we measured the concentration of armodafinil (the most active form of modafinil) in human milk and infant plasma to quantify infant exposure....
The participant was a 30-year-old primipara with narcolepsy, taking modafinil (300 mg morning, 100 mg noon) while breastfeeding her 6-week-old infant despite the paucity of safety information. Armodaf...
Based on these findings, relatively small amounts of armodafinil pass into human milk, with consequent limited infant exposure. Consideration can be given to the use of modafinil or armodafinil during...
Modafinil analogs with either a sulfoxide or sulfide moiety have improved binding affinities at the human dopamine transporter (hDAT) compared to modafinil, with lead sulfoxide-substituted analogs sho...
Attention deficit hyperactivity disorder (ADHD) is one of the most common worldwide mental disorders in children, young and adults. If left untreated, the disorder can continue into adulthood. The abu...
Modafinil is a common treatment for excessive daytime sleepiness (EDS) in narcolepsy. The long-term use of modafinil can lead to tolerance with the loss of efficacy and the continuous increase of its ...
Narcolepsy patients on monotherapy with modafinil who developed symptoms of tolerance were eligible. The following alternating therapy regimen was established: Monday to Friday patients continued on m...
41 patients aged 30.9 ± 5.6 years were included. After three months of the alternating therapy regimen, the symptoms of tolerance decreased and the modafinil dose could be reduced by 41% (p < 0.01) re...
Patients with tolerance to modafinil could benefit from pitolisant-supported bridging during drug holidays. This alternating pharmacological strategy proved to be safe and helped to reduce EDS and to ...
Clinical Trials.gov Identifier NCT05321355....
Fatigue remains an important factor in major aviation accidents. Stimulants may counteract fatigue's adverse effects, with modafinil as a promising alternative to caffeine. However, the effect of a si...
This study aims to determine the effect of 200 mg modafinil on vigilance during a limited period of sleep deprivation compared to 300 mg caffeine and placebo....
Thirty-two volunteers of the Royal Netherlands Air Force (RNLAF) were double-blindly administered modafinil, caffeine, and placebo on three non-consecutive trial days after being awake for median 17 h...
This study revealed statistically significant effects of caffeine and modafinil compared with placebo on all endpoints, except for VigTrack mean tracking error. PVT results were less impaired 2 h afte...
The present study demonstrates that 200 mg modafinil and 300 mg caffeine significantly decrease the effects of a limited period of sleep deprivation on vigilance compared with placebo. Although PVT pa...
Modafinil (MOD) is a CNS stimulant used for the treatment of narcolepsy, shift work sleep disorder, excessive daytime sleepiness, and post-COVID 19 neurological symptoms. In the literature, there is n...
Stimulants like methylphenidate, modafinil, and caffeine have repeatedly shown to enhance cognitive processes such as attention and memory. However, brain-functional mechanisms underlying such cogniti...
The neuro-stimulant anti-narcoleptic drug as modafinil (MOD) is used to treatment neurological conditions caused by COVID-19. MOD was used to treatment narcolepsy, shift-work sleep disorder, and obstr...